PURPOSE: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma. DESIGN: Prospective, observational cohort study. PARTICIPANTS: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. METHODS: Detailed medical history was obtained from each patient. All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months and the data of drop usage was downloaded using software provided with the dosing aid. Data were analyzed for the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit. MAIN OUTCOME MEASURES: Assessment of adherence and patterns of drop usage as indicated by the DA. RESULTS: A total of 282 subjects consented to be in the study and 86 (30%) withdrew before study completion or had device errors, leaving 196 subjects (70%) with evaluable data at 3 months. The overall mean (+/-standard deviation) adherence rate was 0.71 (+/-0.24), ranging from 0.02 to 0.97. One hundred nine of these patients (55.6%) took greater than 75% of the expected doses. Those with adherence of less than 50% of expected doses showed substantially increased dose taking immediately after the office visit and just before the return visit at 3 months (P = 0.03). The mean adherence rate estimates of the physician and patient self-report were 0.77 and 0.95, respectively. The agreement between the physician assessment and DA-recorded adherence rate showed poor correlation for individual cases (intraclass correlation coefficient, 0.09; 95% confidence interval, 0.00-0.19). CONCLUSIONS: Nearly 45% of patients using an electronic monitoring device who knew they were being monitored and were provided free medication used their drops less than 75% of the time. Patients reported far higher medication use than their actual behavior. The ability of the physician to identify which persons are poorly adherent from their self-report or from other subjective clues is poor. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
PURPOSE: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma. DESIGN: Prospective, observational cohort study. PARTICIPANTS: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. METHODS: Detailed medical history was obtained from each patient. All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months and the data of drop usage was downloaded using software provided with the dosing aid. Data were analyzed for the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit. MAIN OUTCOME MEASURES: Assessment of adherence and patterns of drop usage as indicated by the DA. RESULTS: A total of 282 subjects consented to be in the study and 86 (30%) withdrew before study completion or had device errors, leaving 196 subjects (70%) with evaluable data at 3 months. The overall mean (+/-standard deviation) adherence rate was 0.71 (+/-0.24), ranging from 0.02 to 0.97. One hundred nine of these patients (55.6%) took greater than 75% of the expected doses. Those with adherence of less than 50% of expected doses showed substantially increased dose taking immediately after the office visit and just before the return visit at 3 months (P = 0.03). The mean adherence rate estimates of the physician and patient self-report were 0.77 and 0.95, respectively. The agreement between the physician assessment and DA-recorded adherence rate showed poor correlation for individual cases (intraclass correlation coefficient, 0.09; 95% confidence interval, 0.00-0.19). CONCLUSIONS: Nearly 45% of patients using an electronic monitoring device who knew they were being monitored and were provided free medication used their drops less than 75% of the time. Patients reported far higher medication use than their actual behavior. The ability of the physician to identify which persons are poorly adherent from their self-report or from other subjective clues is poor. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Authors: A M Eaton; G M Gordon; A Konowal; A Allen; M Allen; A Sgarlata; G Gao; H Wafapoor; R L Avery Journal: Eye (Lond) Date: 2015-09-11 Impact factor: 3.775
Authors: Catherine Slota; Robyn Sayner; Michelle Vitko; Delesha M Carpenter; Susan J Blalock; Alan L Robin; Kelly W Muir; Mary Elizabeth Hartnett; Betsy Sleath Journal: Optom Vis Sci Date: 2015-05 Impact factor: 1.973
Authors: Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein Journal: Ophthalmology Date: 2015-08-25 Impact factor: 12.079
Authors: Levi N Kanu; Inae Jang; Daniel J Oh; Manpreet S Tiwana; Amy A Mehta; Mark S Dikopf; Thasarat S Vajaranant; Ahmad A Aref; Deepak P Edward Journal: JAMA Ophthalmol Date: 2020-04-01 Impact factor: 7.389
Authors: Paula A Newman-Casey; John A Musser; Leslie M Niziol; Michele M Heisler; Shivani S Kamat; Manjool M Shah; Nish Patel; Amy M Cohn Journal: J Glaucoma Date: 2019-05 Impact factor: 2.503